Excess body weight—including overweight and obesity—is a significant risk factor for cancer. Research from the American Cancer Society estimates that it contributes to approximately 5 percent of ...
In a first-of-its-kind initiative, MSD Pharmaceuticals and Delhi Capitals proudly announce their partnership to raise awareness about cervical cancer prevention across India. This collaboration aims ...
A new University of Kentucky Markey Cancer Center study provides important insights for future clinical trials in treating ...
Mississippi, a state known for rich culture and strong heritage, also faces some of the nation’s most glaring health ...
Gut bacteria are to blame for the failure of immune checkpoint therapy for ovarian cancer, new research reveals.
Scottish Medicines Consortium approves Libtayo as second-line treatment for advanced cervical cancer
Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo® (cemiplimab) for use on the National Health Service as a second-line monotherapy treatment for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback